Candel Therapeutics, Inc.
CADL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 0% | – |
| Cost of Goods Sold | $1 | $24 | $0 | $15 |
| Gross Profit | -$1 | -$24 | $0 | -$14 |
| % Margin | – | – | 100% | -11,575.2% |
| R&D Expenses | $19 | $25 | $21 | $15 |
| G&A Expenses | $14 | $14 | $14 | $10 |
| SG&A Expenses | $14 | $14 | $14 | $11 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $1 |
| Other Operating Expenses | -$1 | -$25 | $0 | -$15 |
| Operating Expenses | $32 | $14 | $35 | $11 |
| Operating Income | -$33 | -$38 | -$35 | -$26 |
| % Margin | – | – | -27,777.6% | -20,580.8% |
| Other Income/Exp. Net | -$22 | $0 | $16 | -$10 |
| Pre-Tax Income | -$55 | -$38 | -$19 | -$36 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55 | -$38 | -$19 | -$36 |
| % Margin | – | – | -15,035.2% | -28,899.2% |
| EPS | -1.74 | -1.31 | -0.099 | -1.26 |
| % Growth | -32.8% | -1,217.9% | 92.1% | – |
| EPS Diluted | -1.74 | -1.31 | -0.099 | -1.26 |
| Weighted Avg Shares Out | 32 | 29 | 29 | 29 |
| Weighted Avg Shares Out Dil | 32 | 29 | 29 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $1 | $0 |
| Interest Expense | $2 | $1 | $2 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$52 | -$37 | -$16 | -$25 |
| % Margin | – | – | -13,046.4% | -20,395.2% |